Aalberts: highlights ING Benelux Conference Brussels 2024, Ackermans & Van Haaren: Highlights ING Benelux Conference Brussels,Ackermans & Van Haaren: Strong operational performance of underlying companies and guidance fine-tuned upwards, AMG: Highlights ING Benelux Conference Brussels, Aperam: Highlights ING Benelux Conference Brussels, Arcadis: Highlights ING Benelux conference, Azelis: Highlights ING Benelux Conference Brussels, Bekaert: Guidance cut and €200m buyback as sweetener, CFE: No new...
Montea invests EUR 29.7m in two prime locations in the Netherlands. In Diemen, Montea has acquired a highly coveted plot comprising c. 28k sqm, which will be let on a long-term lease to the current tenant. In Oss, Montea will develop a distribution center for Vos Logistics. This will add to the company's two existing properties in the same area. Montea targets to achieve an average initial yield of 6.9% across the two investments. Montea recently updated its Track27 program and estimated that 35...
>Positive phase II results - Argenx has announced positive results for the phase II of the phase II/III study (ALKIVIA) evaluating efgartigimod in patients with three sub-types of idiopathic inflammatory myopathies (or myositis). With no quantified press release for the time being, the group has indicated that the study demonstrates a statistically significant therapeutic effect in favour of efgartigimod on the total improvement score (TIS) at week 24 (primary endpoin...
>Résultats de phase 2 positifs - Argenx annonce des résultats positifs de la partie phase 2 de la phase 2/3 (ALKIVIA) évaluant efgartigimod chez des patients dans trois sous-types de myopathies inflammatoires idiopathiques (ou myosites). Sans communiqué de résultats chiffrés à ce stade, la société indique que l’étude a démontré un effet thérapeutique en faveur d’efgartigimod statistiquement significatif sur le score total d’amélioration (TIS) à la semaine 24 (critère ...
argenx announced that it is advancing clinical development of SC efgar in idiopathic inflammatory myopathies (myositis). The ongoing seamless Ph2/3 study is a basket trial across three myositis subsets, IMNM, ASyS and DM, each of which will continue into the Ph3 part. Furthermore, following the strong Q3 update, we have adjusted our model to reflect the sustained strong commercial uptake for Vyvgart in myasthenia gravis (MG), as well as the solid start in CIDP. On the other hand, we have removed...
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise...
We maintain our Outperform rating on CaixaBank, one of our Top Picks in the sector, with a higher target of € 7.2 vs € 6.7 and ahead of the CMD on 19 November. We are lifting our net income estimates by 7% for 2025-2026, to 7% above the consensus. The strategic update is set to highlight the wisdom of the business model diversification (long-term savings) to address the current transition phase on rates. Despite a solid market performance, the profile does not look to be fully reflec...
Nous réitérons notre opinion Surperformance sur CaixaBank, l’un de nos top picks du secteur, avec un OC porté à 7.2 € vs 6.7 € et en amont du CMD du 19/11. Nous relevons nos anticipations de RN de 7% sur 2025/2026 qui ressortent 7% supérieures au consensus. L’update stratégique devrait mettre en avant la pertinence de la diversification du business model (épargne LT) face à la transition actuelle sur les taux. Malgré un solide parcours boursier, cela n’est pas pleinement reflété dans ...
>PSOE and Sumar spring a surprise in seeking to suddenly abolish the SOCIMI regime - On Monday 11 November, the PSOE reached a tax agreement with its Spanish government ally, “Sumar”, whereby the two parties want to abolish the SOCIMI REIT regime or at least part of its tax advantages. This sudden stance, which surprised Spanish property professionals, is thus different from the position that was presented just last week, namely to “encourage the construction of affor...
>PSOE et Sumar créent la surprise en voulant supprimer soudainement le régime SOCIMI - Ce lundi 11 novembre, le PSOE sont parvenus à un accord fiscal avec son allié au gouvernement espagnol, « Sumar », par lequel les deux partis veulent supprimer le régime SOCIMI ou au moins une partie de ses avantages fiscaux. Cette prise de position soudaine qui a crée la surprise auprès des professionnels de l’immobilier espagnol, diffère ainsi de la position qui était encore mise ...
Yesterday before US market opens, argenx and partner Zai Lab announced China's national medical products administration (NMPA) approved the supplemental (sBLA) for Vyvgart Hytrulo in adults with CIDP. We anticipate approx. $600m in peak sales for CIDP in China, and pencil down 15% royalties to argenx from Zai Lab. Looking ahead, the candidate has been submitted to regulatory agencies in Europe and Japan, with approvals in CIDP expected in 2025, while regulatory submission in Canada is due by YE2...
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa inject...
Exmar published a good set of 9m24 results last Friday after close. EBITDA (IFRS) landed at $95.7m (up from $54.4m in 9m23). Corrected for the $19.6m capital gain on the Bexco disposal, EBITDA grew from $54.4m to $76.1m with growth realised in all three divisions. EBIT (IFRS) landed at $68m (vs. $25m in 9m23) and net debt (prop. conso) fell to $227m (vs. $252m per 4Q23). As the share is trading close to our €7.4 TP we upgrade from Reduce to Hold.
A director at Argen X SE sold 1,218 shares at 542.600EUR and the significance rating of the trade was 99/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.